INO insider transaction filings
INOVIO PHARMACEUTICALS, INC. — 47 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-05-21. Screen INO transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-05-21 | 4 | Sumner Michael John — Chief Medical Officer | Option exercise (M): 9,450 · Tax withholding (F): 2,693 @ $1.23 · Option exercise (M): 9,450 (derivative) @ $0 · Grant/award (A): 46,876 (derivative) @ $0 · Grant/award (A): 37,684 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | Shea Jacqueline Elizabeth — Chief Executive Officer, Director | Option exercise (M): 28,296 · Tax withholding (F): 12,306 @ $1.23 · Option exercise (M): 28,296 (derivative) @ $0 · Grant/award (A): 123,760 (derivative) @ $0 · Grant/award (A): 100,240 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | Miller Ann Calby — Director | Grant/award (A): 41,800 (derivative) @ $0 · Grant/award (A): 34,200 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | Humeau Laurent — Chief Scientific Officer | Option exercise (M): 6,027 · Tax withholding (F): 2,163 @ $1.23 · Option exercise (M): 6,027 (derivative) @ $0 · Grant/award (A): 34,160 (derivative) @ $0 · Grant/award (A): 27,440 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | DANSEY ROGER D — Director | Grant/award (A): 41,800 (derivative) @ $0 · Grant/award (A): 34,200 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | Weiner David B. — Director | Grant/award (A): 41,800 (derivative) @ $0 · Grant/award (A): 34,200 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | Shepard Jay — Director | Grant/award (A): 41,800 (derivative) @ $0 · Grant/award (A): 34,200 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | Zoth Lota S. — Director | Grant/award (A): 41,800 (derivative) @ $0 · Grant/award (A): 34,200 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | BENITO SIMON X — Director | Grant/award (A): 41,800 (derivative) @ $0 · Grant/award (A): 34,200 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | KIES PETER — CFO | Option exercise (M): 8,700 · Tax withholding (F): 4,688 @ $1.23 · Option exercise (M): 8,700 (derivative) @ $0 · Grant/award (A): 39,760 (derivative) @ $0 · Grant/award (A): 32,480 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | YARNO WENDY L — Director | Grant/award (A): 41,800 (derivative) @ $0 · Grant/award (A): 34,200 (derivative) @ $0 | EDGAR |
| 2026-05-18 | 4 | Sumner Michael John — Chief Medical Officer | Option exercise (M): 2,385 · Tax withholding (F): 680 @ $1.30 · Option exercise (M): 2,385 (derivative) @ $0 | EDGAR |
| 2026-05-18 | 4 | Shea Jacqueline Elizabeth — Chief Executive Officer, Director | Option exercise (M): 17,744 · Tax withholding (F): 7,717 @ $1.30 · Option exercise (M): 17,744 (derivative) @ $0 | EDGAR |
| 2026-05-18 | 4 | Humeau Laurent — Chief Scientific Officer | Option exercise (M): 4,771 · Tax withholding (F): 1,712 @ $1.30 · Option exercise (M): 4,771 (derivative) @ $0 | EDGAR |
| 2026-05-18 | 4 | KIES PETER — CFO | Option exercise (M): 4,771 · Tax withholding (F): 2,571 @ $1.30 · Option exercise (M): 4,771 (derivative) @ $0 | EDGAR |
| 2026-04-01 | 4 | Sumner Michael John — Chief Medical Officer | Option exercise (M): 4,292 · Tax withholding (F): 1,223 @ $1.74 · Option exercise (M): 4,292 (derivative) @ $0 | EDGAR |
| 2026-03-05 | 4 | Sumner Michael John — Chief Medical Officer | Grant/award (A): 36,832 (derivative) @ $0 · Grant/award (A): 29,608 (derivative) @ $0 | EDGAR |
| 2026-03-05 | 4 | Shea Jacqueline Elizabeth — Chief Executive Officer, Director | Grant/award (A): 97,240 (derivative) @ $0 · Grant/award (A): 78,760 (derivative) @ $0 | EDGAR |
| 2026-03-05 | 4 | Humeau Laurent — Chief Scientific Officer | Grant/award (A): 26,840 (derivative) @ $0 · Grant/award (A): 21,560 (derivative) @ $0 | EDGAR |
| 2026-03-05 | 4 | KIES PETER — CFO | Grant/award (A): 31,240 (derivative) @ $0 · Grant/award (A): 25,520 (derivative) @ $0 | EDGAR |
| 2026-02-27 | 4 | Sumner Michael John — Chief Medical Officer | Option exercise (M): 5,010 · Option exercise (M): 11,550 · Tax withholding (F): 3,903 @ $1.79 · Option exercise (M): 5,010 (derivative) @ $0 · Option exercise (M): 11,550 (derivative) @ $0 | EDGAR |
| 2026-02-27 | 4 | Shea Jacqueline Elizabeth — Chief Executive Officer, Director | Option exercise (M): 18,632 · Tax withholding (F): 8,057 @ $1.79 · Option exercise (M): 28,401 · Tax withholding (F): 13,657 @ $1.79 · Option exercise (M): 18,632 (derivative) @ $0 · Option exercise (M): 28,401 (derivative) @ $0 | EDGAR |
| 2026-02-27 | 4 | Humeau Laurent — Chief Scientific Officer | Option exercise (M): 5,010 · Tax withholding (F): 2,064 @ $1.79 · Option exercise (M): 7,366 · Tax withholding (F): 3,034 @ $1.79 · Option exercise (M): 5,010 (derivative) @ $0 · Option exercise (M): 7,366 (derivative) @ $0 | EDGAR |
| 2026-02-27 | 4 | Weiner David B. — Director | Option exercise (M): 972 · Option exercise (M): 972 (derivative) @ $0 | EDGAR |
| 2026-02-27 | 4 | KIES PETER — CFO | Option exercise (M): 5,010 · Tax withholding (F): 2,965 @ $1.79 · Option exercise (M): 10,634 · Tax withholding (F): 6,294 @ $1.79 · Option exercise (M): 5,010 (derivative) @ $0 · Option exercise (M): 10,634 (derivative) @ $0 | EDGAR |
| 2025-07-01 | 4 | Sumner Michael John — Chief Medical Officer | Option exercise (M): 2,916 · Option exercise (M): 2,916 (derivative) @ $0 | EDGAR |
| 2025-05-21 | 4 | Shea Jacqueline Elizabeth — Chief Executive Officer, Director | Grant/award (A): 84,888 (derivative) @ $0 · Grant/award (A): 105,262 (derivative) @ $0 | EDGAR |
| 2025-05-21 | 4 | Humeau Laurent — Chief Scientific Officer | Grant/award (A): 18,081 (derivative) @ $0 · Grant/award (A): 22,419 (derivative) @ $0 | EDGAR |
| 2025-05-21 | 4 | Zoth Lota S. — Director | Option exercise (M): 2,167 · Option exercise (M): 2,167 (derivative) @ $0 | EDGAR |
| 2025-05-21 | 4 | Miller Ann Calby — Director | Option exercise (M): 2,167 · Option exercise (M): 2,167 (derivative) @ $0 | EDGAR |
| 2025-05-21 | 4 | Shepard Jay — Director | Option exercise (M): 2,167 · Option exercise (M): 2,167 (derivative) @ $0 | EDGAR |
| 2025-05-21 | 4 | BENITO SIMON X — Director | Option exercise (M): 2,167 · Option exercise (M): 2,167 (derivative) @ $0 | EDGAR |
| 2025-05-21 | 4 | YARNO WENDY L — Director | Option exercise (M): 2,167 · Option exercise (M): 2,167 (derivative) @ $0 | EDGAR |
| 2025-05-21 | 4 | KIES PETER — CFO | Grant/award (A): 26,100 (derivative) @ $0 · Grant/award (A): 31,950 (derivative) @ $0 | EDGAR |
| 2025-05-21 | 4 | DANSEY ROGER D — Director | Option exercise (M): 2,167 · Option exercise (M): 2,167 (derivative) @ $0 | EDGAR |
| 2025-05-21 | 4 | Sumner Michael John — Chief Medical Officer | Grant/award (A): 28,350 (derivative) @ $0 · Grant/award (A): 35,100 (derivative) @ $0 | EDGAR |
| 2025-05-21 | 4 | Weiner David B. — Director | Option exercise (M): 2,167 · Option exercise (M): 2,167 (derivative) @ $0 | EDGAR |
| 2025-05-16 | 4 | Sumner Michael John — Chief Medical Officer | Option exercise (M): 2,385 · Tax withholding (F): 680 @ $1.95 · Option exercise (M): 2,385 (derivative) @ $0 | EDGAR |
| 2025-05-16 | 4 | Shea Jacqueline Elizabeth — Chief Executive Officer, Director | Option exercise (M): 17,744 · Tax withholding (F): 7,717 @ $1.95 · Option exercise (M): 17,744 (derivative) @ $0 | EDGAR |
| 2025-05-16 | 4 | KIES PETER — CFO | Option exercise (M): 4,771 · Tax withholding (F): 2,566 @ $1.95 · Option exercise (M): 4,771 (derivative) @ $0 | EDGAR |
| 2025-05-16 | 4 | Humeau Laurent — Chief Scientific Officer | Option exercise (M): 4,771 · Tax withholding (F): 1,708 @ $1.95 · Option exercise (M): 4,771 (derivative) @ $0 | EDGAR |
| 2025-05-12 | 4 | Shea Jacqueline Elizabeth — Chief Executive Officer, Director | Option exercise (M): 5,500 · Tax withholding (F): 2,392 @ $1.80 · Option exercise (M): 5,500 (derivative) @ $0 | EDGAR |
| 2025-02-28 | 4 | Humeau Laurent — Chief Scientific Officer | Option exercise (M): 3,855 · Tax withholding (F): 1,584 @ $1.98 · Option exercise (M): 5,010 · Tax withholding (F): 2,059 @ $1.98 · Option exercise (M): 3,855 (derivative) @ $0 · Option exercise (M): 5,010 (derivative) @ $0 · +2 more | EDGAR |
| 2025-02-28 | 4 | Sumner Michael John — Chief Medical Officer | Option exercise (M): 5,010 · Option exercise (M): 5,010 (derivative) @ $0 · Grant/award (A): 42,900 (derivative) @ $0 · Grant/award (A): 34,650 (derivative) @ $0 | EDGAR |
| 2025-02-28 | 4 | Shea Jacqueline Elizabeth — Chief Executive Officer, Director | Option exercise (M): 5,852 · Tax withholding (F): 2,493 @ $1.98 · Option exercise (M): 18,632 · Tax withholding (F): 9,088 @ $1.98 · Option exercise (M): 5,852 (derivative) @ $0 · Option exercise (M): 18,632 (derivative) @ $0 · +2 more | EDGAR |
| 2025-02-28 | 4 | KIES PETER — CFO | Option exercise (M): 3,997 · Tax withholding (F): 2,362 @ $1.98 · Option exercise (M): 5,010 · Tax withholding (F): 2,960 @ $1.98 · Option exercise (M): 3,997 (derivative) @ $0 · Option exercise (M): 5,010 (derivative) @ $0 · +2 more | EDGAR |
| 2025-02-28 | 4 | Weiner David B. — Director | Option exercise (M): 972 · Option exercise (M): 972 · Option exercise (M): 972 (derivative) @ $0 · Option exercise (M): 972 (derivative) @ $0 | EDGAR |
Recent 8-K events — INOVIO PHARMACEUTICALS, INC.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-31 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-29 | 8-K | 2.02 — Results of Operations and Financial Condition | EDGAR |
| 2026-05-20 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-06 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-02 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-03-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-27 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.03 — Material Modification to Rights of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-29 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=INO returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →